Form 4: Nuvation Bio Inc. Executive Moses Makunje Reports Stock Option Grant

Moses Makunje, VP of Finance at Nuvation Bio Inc., reports the acquisition of 250,000 Class A Common Stock options.

Summary

• On February 29, 2024, Moses Makunje, VP of Finance at Nuvation Bio Inc., was granted options to purchase 250,000 shares of Class A Common Stock at an exercise price of $1.87.
• The options vest 25% on the one-year anniversary of the grant date (February 29, 2024), and then monthly over the subsequent 36 months, contingent upon continuous service.
• Following this transaction, Makunje directly owns derivative securities for 250,000 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation and has a neutral sentiment.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is typical for a VP level executive.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotech companies.
• The vesting schedule of 25% after one year followed by monthly vesting over the next 36 months is a common practice.
• The size of the grant is likely benchmarked against similar roles and company size within the biotech industry.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders.
• The grant incentivizes the executive to contribute to the company's success, potentially benefiting all stakeholders.

Key Dates